2017
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaB-cell lymphoma 2Advanced cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsHDAC inhibitionT-cell lymphoma patientsNovel BCL2 inhibitorPeripheral blood involvementAvailable systemic therapiesWorse clinical outcomesTreatment of patientsNon-Hodgkin lymphomaT-cell lymphomaCTCL cell linesPotential therapeutic targetHistone deacetylase inhibitionQuality of lifeHistone deacetylase inhibitorsBlood involvementSystemic therapyClinical outcomesTumor burdenLymphoma patientsCombination therapyBCL2 inhibitors
2008
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsApoptosisBexaroteneClone CellsCytokinesDendritic CellsDiphtheria ToxinGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-2Lymphoma, T-Cell, CutaneousMiceNeoplastic Stem CellsPhotopheresisPUVA TherapyRecombinant Fusion ProteinsTetrahydronaphthalenesT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsCutaneous T-cell lymphomaSheep red blood cellsT-cell lymphomaNew therapeutic approachesBasic science techniquesRed blood cellsClinical featuresTherapeutic optionsT lymphocytesCell lymphomaTherapeutic approachesClinical practiceImmune systemMalignant cellsTherapeutic opportunitiesBlood cellsPatientsImmunobiologyDiseaseMolecular demonstrationCurrent understandingCellsLymphomaLymphocytesImmunology
2007
Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice
Wakabayashi Y, Mao JH, Brown K, Girardi M, Balmain A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 2007, 445: 761-765. PMID: 17230190, DOI: 10.1038/nature05489.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsApoptosisCarcinoma, Squamous CellCell LineCell Transformation, NeoplasticCrosses, GeneticFemaleGene Expression Regulation, NeoplasticGenes, rasHSP40 Heat-Shock ProteinsHumansKruppel-Like Transcription FactorsMaleMiceMice, Inbred C57BLMice, TransgenicMolecular Sequence DataPatched ReceptorsPatched-1 ReceptorPolymorphism, GeneticRas ProteinsReceptors, Cell SurfaceZinc Finger Protein Gli2ConceptsSquamous carcinomaTumor suppressor geneFVB/N miceSonic hedgehogSuppressor geneFVB/N strainBasal cell carcinomaPTCH geneSame target cellsCell lineage commitmentPatched geneHuman patched geneHost genetic backgroundClassical tumor suppressor geneCell carcinomaPtch alleleFVB miceN miceCarcinogen exposureC57BL/6 strainTumor typesLineage commitmentMouse homologueHybrid miceGenetic basis